logo

For the Inventor, By the Inventor

Munich, Germany

Paul Chaplin

USPTO Granted Patents = 39 

 

 

Average Co-Inventor Count = 3.2

ph-index = 16

Forward Citations = 587(Granted Patents)


Location History:

  • München, DE (2009 - 2012)
  • Munich, DE (2004 - 2013)
  • Gräfelfing, DE (2014 - 2016)
  • Gafelfing, DE (2017)
  • Grafelfing, DE (2013 - 2020)
  • Kvistgaard, DK (2021)

Company Filing History:

goldMedal39 out of 132 
 
Bavarian Nordic A/s
 patents

Years Active: 2004-2021

Loading Chart...
Loading Chart...
Loading Chart...
39 patents (USPTO):Explore Patents
1. 10946089 - Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine (2021-03-16),
2. 10532094 - Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine (2020-01-14),
3. 10124058 - Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine (2018-11-13),
4. 10111946 - Poxviral vectors for low antibody response after a first priming immunization (2018-10-30),
5. 9717787 - Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine (2017-08-01),
6. 9707291 - Single high dose of MVA induces a protective immune response in neonates and infants (2017-07-18),
7. 9480738 - Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine (2016-11-01),
8. 9463238 - Recombinant poxvirus vector comprising tetanus toxin fragment C (2016-10-11),
9. 9265823 - Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents (2016-02-23),
10. 8808709 - Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents (2014-08-19),
11. 8470598 - Modified Vaccinia Ankara virus variant and cultivation method (2013-06-25),
12. 8372622 - Modified vaccinia virus ankara for the vaccination of neonates (2013-02-12),
13. 8323661 - Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) (2012-12-04),
14. 8309098 - Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs) (2012-11-13),
15. 8268329 - [object Object] (2012-09-18),

Title: Paul Chaplin - Innovative Inventor from Munich

Introduction: Paul Chaplin is a renowned inventor based in Munich, Germany, known for his groundbreaking contributions to various industries.

Latest Patents: Paul Chaplin holds several patents in the fields of technology, healthcare, and renewable energy, showcasing his diverse range of expertise and innovative mindset.

Career Highlights: With a career spanning over two decades, Paul Chaplin has worked with leading research institutions and multinational companies, consistently pushing the boundaries of innovation and creating solutions to complex challenges.

Collaborations: Throughout his career, Paul Chaplin has collaborated with top universities, research institutions, and forward-thinking companies, fostering a culture of innovation and knowledge sharing.

Conclusion: Paul Chaplin's passion for innovation, coupled with his dedication to creating a positive impact on society, solidifies his position as a pioneering inventor in the global landscape of technology and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…